Fresenius Group in the news

Fresenius Medical Care's stock plummeted following the unexpected departure of CEO Helen Giza and the appointment of Shervin Korangy.

Shervin Korangy is replacing Helen Giza as the CEO of Fresenius Medical Care (FMC) starting October 12, as Giza departs after four years.

Fresenius Medical Care appointed Shervin J. Korangy as CEO, replacing Helen Giza, effective October 12, 2026.

Helen Giza is abruptly exiting as CEO of Fresenius Medical Care and will be replaced by supervisory board member Shervin Korangy, effective October 12, 2026.

Fresenius Medical Care appoints Shervin J. Korangy as the new CEO, succeeding Helen Giza, to accelerate growth and innovation.

Shervin J. Korangy is appointed CEO of Fresenius Medical Care, succeeding Helen Giza, to lead the company's next phase of profitable growth and innovation after her successful transformation efforts.

Fresenius Medical Care (FMC) St stock rose by 0.6% to 40.43 EUR, with Q2 2026 earnings per share at 0.81 EUR and revenue at 4.86 billion EUR.

Helen Giza is abruptly leaving Fresenius Medical Care as CEO after almost four years due to concerns over growth strategy.

Fresenius stock saw a minor pre-market dip while the company finalized its acquisition of the remaining 45% of mAbxience for up to EUR 750 million, securing full ownership of its biosimilars platform.

Fresenius Ventures appointed Nipun Juneja as Investment Strategy Director, responsible for fund strategy, investment theses, and driving investment in medtech and other areas.

Vizient expanded its IV fluid supply assurance program by partnering with Fresenius Kabi to provide dedicated inventory and strengthen supply continuity for critical products.

Fresenius finalized the acquisition of mAbxience for up to EUR 750 million, boosting its biosimilars segment, while reporting increased Q2 2026 revenues and EBIT, though its stock remains below its annual high.

Jefferies maintained a 'Buy' rating for Fresenius SE with a 55 Euro price target, expecting discussions on business dynamics, future prospects of Biosimilars, Medtech, and Nutrition, and growth sustainability, while the stock showed a 1.4% increase but a 9.6% year-to-date decline.

Fresenius Medical Care (FMC) St stock experienced a slight increase, with its price currently between its 52-week high and low, while the company anticipates a dividend and reported increased earnings and revenue for the second quarter of 2026.

Fresenius acquired full ownership of mAbxience for up to EUR 750 million, expects immediate EPS accretion, and reported strong Q2/2026 results with raised full-year core EPS guidance.

Fresenius completed the acquisition of the remaining 45 percent of mAbxience for up to EUR 750 million, gaining full ownership of its biosimilars platform, with stock gaining 1.47 percent and Q2 2026 revenue up 6.00 percent.

Nipun Juneja joins Fresenius Ventures as investment strategy director to shape fund strategy and drive investment in medtech and beyond, with the fund investing —40M annually.

Fresenius' stock gained after completing the acquisition of mAbxience, a biosimilar company, which is expected to boost earnings.

Fresenius fully acquired mAbxience for up to EUR 750 million, expanding its biosimilars platform and upgrading its 2026 earnings guidance.

Fresenius Medical Care stock showed a bearish signal and declined, while the company is a global leader in dialysis products and services.